Prostate Cancer最新文献_第10页

Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer. 血液中omega-3脂肪酸作为前列腺癌风险决定因素的分子生物标志物。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-03-25 DOI: 10.1155/2013/875615

Mishell Kris Sorongon-Legaspi, Michael Chua, Maria Christina Sio, Marcelino Morales

{"title":"Blood level omega-3 Fatty acids as risk determinant molecular biomarker for prostate cancer.","authors":"Mishell Kris Sorongon-Legaspi, Michael Chua, Maria Christina Sio, Marcelino Morales","doi":"10.1155/2013/875615","DOIUrl":"https://doi.org/10.1155/2013/875615","url":null,"abstract":"Previous researches involving dietary methods have shown conflicting findings. Authors sought to assess the association of prostate cancer risk with blood levels of omega-3 polyunsaturated fatty acids (n-3 PUFA) through a meta-analysis of human epidemiological studies in available online databases (July, 2012). After critical appraisal by two independent reviewers, Newcastle-Ottawa Quality Assessment Scale (NOQAS) was used to grade the studies. Six case control and six nested case control studies were included. Results showed nonsignificant association of overall effect estimates with total or advanced prostate cancer or high-grade tumor. High blood level of alpha-linolenic acid (ALA) had nonsignificant positive association with total prostate cancer risk. High blood level of docosapentaenoic acid (DPA) had significant negative association with total prostate cancer risk. Specific n-3 PUFA in fish oil, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) had positive association with high-grade prostate tumor risk only after adjustment of interstudy variability. There is evidence that high blood level of DPA that is linked with reduced total prostate cancer risk and elevated blood levels of fish oils, EPA, and DHA is associated with high-grade prostate tumor, but careful interpretation is needed due to intricate details involved in prostate carcinogenesis and N-3 PUFA metabolism.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"875615"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/875615","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31360956","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 19

Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent. 非洲裔男性前列腺癌发病率、侵袭性和死亡率的全球模式。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-02-13 DOI: 10.1155/2013/560857

Timothy R Rebbeck, Susan S Devesa, Bao-Li Chang, Clareann H Bunker, Iona Cheng, Kathleen Cooney, Rosalind Eeles, Pedro Fernandez, Veda N Giri, Serigne M Gueye, Christopher A Haiman, Brian E Henderson, Chris F Heyns, Jennifer J Hu, Sue Ann Ingles, William Isaacs, Mohamed Jalloh, Esther M John, Adam S Kibel, Lacreis R Kidd, Penelope Layne, Robin J Leach, Christine Neslund-Dudas, Michael N Okobia, Elaine A Ostrander, Jong Y Park, Alan L Patrick, Catherine M Phelan, Camille Ragin, Robin A Roberts, Benjamin A Rybicki, Janet L Stanford, Sara Strom, Ian M Thompson, John Witte, Jianfeng Xu, Edward Yeboah, Ann W Hsing, Charnita M Zeigler-Johnson

{"title":"Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of african descent.","authors":"Timothy R Rebbeck, Susan S Devesa, Bao-Li Chang, Clareann H Bunker, Iona Cheng, Kathleen Cooney, Rosalind Eeles, Pedro Fernandez, Veda N Giri, Serigne M Gueye, Christopher A Haiman, Brian E Henderson, Chris F Heyns, Jennifer J Hu, Sue Ann Ingles, William Isaacs, Mohamed Jalloh, Esther M John, Adam S Kibel, Lacreis R Kidd, Penelope Layne, Robin J Leach, Christine Neslund-Dudas, Michael N Okobia, Elaine A Ostrander, Jong Y Park, Alan L Patrick, Catherine M Phelan, Camille Ragin, Robin A Roberts, Benjamin A Rybicki, Janet L Stanford, Sara Strom, Ian M Thompson, John Witte, Jianfeng Xu, Edward Yeboah, Ann W Hsing, Charnita M Zeigler-Johnson","doi":"10.1155/2013/560857","DOIUrl":"10.1155/2013/560857","url":null,"abstract":"Prostate cancer (CaP) is the leading cancer among men of African descent in the USA, Caribbean, and Sub-Saharan Africa (SSA). The estimated number of CaP deaths in SSA during 2008 was more than five times that among African Americans and is expected to double in Africa by 2030. We summarize publicly available CaP data and collected data from the men of African descent and Carcinoma of the Prostate (MADCaP) Consortium and the African Caribbean Cancer Consortium (AC3) to evaluate CaP incidence and mortality in men of African descent worldwide. CaP incidence and mortality are highest in men of African descent in the USA and the Caribbean. Tumor stage and grade were highest in SSA. We report a higher proportion of T1 stage prostate tumors in countries with greater percent gross domestic product spent on health care and physicians per 100,000 persons. We also observed that regions with a higher proportion of advanced tumors reported lower mortality rates. This finding suggests that CaP is underdiagnosed and/or underreported in SSA men. Nonetheless, CaP incidence and mortality represent a significant public health problem in men of African descent around the world.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"560857"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3583061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31295120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study. HNF1B变异和肥胖可能影响非裔美国男性前列腺癌风险:一项初步研究

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-12-09 DOI: 10.1155/2013/384594

Ganna Chornokur, Ernest K Amankwah, Stacy N Davis, Catherine M Phelan, Jong Y Park, Julio Pow-Sang, Nagi B Kumar

{"title":"Variation in HNF1B and Obesity May Influence Prostate Cancer Risk in African American Men: A Pilot Study.","authors":"Ganna Chornokur, Ernest K Amankwah, Stacy N Davis, Catherine M Phelan, Jong Y Park, Julio Pow-Sang, Nagi B Kumar","doi":"10.1155/2013/384594","DOIUrl":"https://doi.org/10.1155/2013/384594","url":null,"abstract":"Background. Prostate cancer (PCa) racial disparity is multifactorial, involving biological, sociocultural, and lifestyle determinants. We investigated the association between selected potentially functional polymorphisms (SNPs) and prostate cancer (PCa) risk in Black (AAM) and White (EAM) men. We further explored if these associations varied by the body mass index (BMI) and height. Methods. Age-matched DNA samples from 259 AAM and 269 EAM were genotyped for 10 candidate SNPs in 7 genes using the TaqMan allelic differentiation analysis. The dominant, recessive, and additive age-adjusted unconditional logistic regression models were fitted. Results. Three SNPs showed statistically significant associations with PCa risk: in AAM, HNF1B rs7501939 (OR = 2.42, P = 0.0046) and rs4430796 (OR = 0.57, P = 0.0383); in EAM, CTBP2 rs4962416 (OR = 1.52, P = 0.0384). In addition, high BMI in AAM (OR = 1.06, P = 0.022) and height in EAM (OR = 0.92, P = 0.0434) showed significant associations. Interestingly, HNF1B rs7501939 was associated with PCa exclusively in obese AAM (OR = 2.14, P = 0.0103). Conclusion. Our results suggest that variation in the HNF1B may influence PCa risk in obese AAM. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"384594"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/384594","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31996611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 18

The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. 血管内皮生长因子在前列腺癌向骨骼转移中的作用。

IF 4.2

Prostate Cancer Pub Date : 2013-01-01 Epub Date: 2013-12-12 DOI: 10.1155/2013/418340

Emma Roberts, Davina A F Cossigny, Gerald M Y Quan

{"title":"The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton.","authors":"Emma Roberts, Davina A F Cossigny, Gerald M Y Quan","doi":"10.1155/2013/418340","DOIUrl":"https://doi.org/10.1155/2013/418340","url":null,"abstract":"Despite the clinical implication and high incidence of bone and spinal metastases, the molecular mechanisms behind prostate cancer metastasis to bone and spine are not well understood. In this review the molecular mechanisms that may contribute to the highly metastatic phenotype of prostate cancer are discussed. Proangiogenic factors such as vascular endothelial growth factor (VEGF) have been shown to not only aid in the metastatic capabilities of prostate cancer but also encourage the colonization and growth of prostate tumour cells in the skeleton. The importance of VEGF in the complex process of prostate cancer dissemination to the skeleton is discussed, including its role in the development of the bone premetastatic niche, metastatic tumour cell recognition of bone, and bone remodeling. The expression of VEGF has also been shown to be upregulated in prostate cancer and is associated with clinical stage, Gleason score, tumour stage, progression, metastasis, and survival. Due to the multifaceted effect VEGF has on tumour angiogenesis, tumour cell proliferation, and bone destruction, therapies targeting the VEGF pathways have shown promising clinical application and are being investigated in clinical trials. ","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2013 ","pages":"418340"},"PeriodicalIF":4.2,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/418340","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"32007000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 99

Androgen deprivation therapy toxicity and management for men receiving radiation therapy. 接受放射治疗的男性雄激素剥夺疗法的毒性和管理。

IF 4.2

Prostate Cancer Pub Date : 2012-01-01 Epub Date: 2012-12-30 DOI: 10.1155/2012/580306

Matthew E Johnson, Mark K Buyyounouski

引用次数: 7

Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial. 局部晚期前列腺癌根治后生化失败的风险分层:来自TROG 96.01试验的数据。

IF 4.2

Prostate Cancer Pub Date : 2012-01-01 Epub Date: 2012-12-24 DOI: 10.1155/2012/814724

Allison Steigler, James W Denham, David S Lamb, Nigel A Spry, David Joseph, John Matthews, Chris Atkinson, Sandra Turner, John North, David Christie, Keen-Hun Tai, Chris Wynne

{"title":"Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 Trial.","authors":"Allison Steigler, James W Denham, David S Lamb, Nigel A Spry, David Joseph, John Matthews, Chris Atkinson, Sandra Turner, John North, David Christie, Keen-Hun Tai, Chris Wynne","doi":"10.1155/2012/814724","DOIUrl":"https://doi.org/10.1155/2012/814724","url":null,"abstract":"Purpose. Survival following biochemical failure is highly variable. Using a randomized trial dataset, we sought to define a risk stratification scheme in men with locally advanced prostate cancer (LAPC). Methods. The TROG 96.01 trial randomized 802 men with LAPC to radiation ± neoadjuvant androgen suppression therapy (AST) between 1996 and 2000. Ten-year follow-up data was used to develop three-tier post-biochemical failure risk stratification schemes based on cutpoints of time to biochemical failure (TTBF) and PSA doubling time (PSADT). Schemes were evaluated in univariable, competing risk models for prostate cancer-specific mortality. The performance was assessed by c-indices and internally validated by the simple bootstrap method. Performance rankings were compared in sensitivity analyses using multivariable models and variations in PSADT calculation. Results. 485 men developed biochemical failure. c-indices ranged between 0.630 and 0.730. The most discriminatory scheme had a high risk category defined by PSADT < 4 months or TTBF < 1 year and low risk category by PSADT > 9 months or TTBF > 3 years. Conclusion. TTBF and PSADT can be combined to define risk stratification schemes after biochemical failure in men with LAPC treated with short-term AST and radiotherapy. External validation, particularly in long-term AST and radiotherapy datasets, is necessary.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2012 ","pages":"814724"},"PeriodicalIF":4.2,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/814724","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31162877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 7

Prostate intrafraction translation margins for real-time monitoring and correction strategies. 前列腺浸润内平移边缘的实时监测和纠正策略。

IF 4.2

Prostate Cancer Pub Date : 2012-01-01 Epub Date: 2011-07-13 DOI: 10.1155/2012/130579

Dale W Litzenberg, James M Balter, Scott W Hadley, Daniel A Hamstra, Twyla R Willoughby, Patrick A Kupelian, Toufik Djemil, Arul Mahadevan, Shirish Jani, Geoffrey Weinstein, Timothy Solberg, Charles Enke, Lisa Levine, Howard M Sandler

{"title":"Prostate intrafraction translation margins for real-time monitoring and correction strategies.","authors":"Dale W Litzenberg, James M Balter, Scott W Hadley, Daniel A Hamstra, Twyla R Willoughby, Patrick A Kupelian, Toufik Djemil, Arul Mahadevan, Shirish Jani, Geoffrey Weinstein, Timothy Solberg, Charles Enke, Lisa Levine, Howard M Sandler","doi":"10.1155/2012/130579","DOIUrl":"https://doi.org/10.1155/2012/130579","url":null,"abstract":"The purpose of this work is to determine appropriate radiation therapy beam margins to account for intrafraction prostate translations for use with real-time electromagnetic position monitoring and correction strategies. Motion was measured continuously in 35 patients over 1157 fractions at 5 institutions. This data was studied using van Herk's formula of (αΣ + γσ') for situations ranging from no electromagnetic guidance to automated real-time corrections. Without electromagnetic guidance, margins of over 10 mm are necessary to ensure 95% dosimetric coverage while automated electromagnetic guidance allows the margins necessary for intrafraction translations to be reduced to submillimeter levels. Factors such as prostate deformation and rotation, which are not included in this analysis, will become the dominant concerns as margins are reduced. Continuous electromagnetic monitoring and automated correction have the potential to reduce prostate margins to 2-3 mm, while ensuring that a higher percentage of patients (99% versus 90%) receive a greater percentage (99% versus 95%) of the prescription dose.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2012 ","pages":"130579"},"PeriodicalIF":4.2,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2012/130579","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"30276518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 22

Factors implicated in radiation therapy failure and radiosensitization of prostate cancer. 前列腺癌放射治疗失败和放射致敏的相关因素。

IF 4.2

Prostate Cancer Pub Date : 2012-01-01 Epub Date: 2011-09-08 DOI: 10.1155/2012/593241

Helmut Bonkhoff

引用次数: 42

The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges. 靶向病灶疗法在低风险前列腺癌治疗中的作用：当前挑战的最新进展。

IF 4.2

Prostate Cancer Pub Date : 2012-01-01 Epub Date: 2012-12-31 DOI: 10.1155/2012/587139

Daniel W Smith, Diliana Stoimenova, Khadijah Eid, Al Barqawi

{"title":"The role of targeted focal therapy in the management of low-risk prostate cancer: update on current challenges.","authors":"Daniel W Smith, Diliana Stoimenova, Khadijah Eid, Al Barqawi","doi":"10.1155/2012/587139","DOIUrl":"10.1155/2012/587139","url":null,"abstract":"Prostate cancer is one of the most prevalent cancers among men in the United States, second only to nonmelanomatous skin cancer. Since prostate-specific antigen (PSA) testing came into widespread use in the late 1980s, there has been a sharp increase in annual prostate cancer incidence. Cancer-specific mortality, though, is relatively low. The majority of these cancers will not progress to mortal disease, yet most men who are diagnosed opt for treatment as opposed to observation or active surveillance (AS). These men are thus burdened with the morbidities associated with aggressive treatments, commonly incontinence and erectile dysfunction, without receiving a mortality benefit. It is therefore necessary to both continue investigating outcomes associated with AS and to develop less invasive techniques for those who desire treatment but without the significant potential for quality-of-life side effects seen with aggressive modalities. The goals of this paper are to discuss the problems of overdiagnosis and overtreatment since the advent of PSA screening as well as the potential for targeted focal therapy (TFT) to bridge the gap between AS and definitive therapies. Furthermore, patient selection criteria for TFT, costs, side effects, and brachytherapy template-guided three-dimensional mapping biopsies (3DMB) for tumor localization will also be explored.","PeriodicalId":20907,"journal":{"name":"Prostate Cancer","volume":"2012 ","pages":"587139"},"PeriodicalIF":4.2,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3549346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31185223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Markers of field cancerization: proposed clinical applications in prostate biopsies. 野癌标志物:前列腺活检的临床应用建议。

IF 4.2

Prostate Cancer Pub Date : 2012-01-01 Epub Date: 2012-05-14 DOI: 10.1155/2012/302894

Kristina A Trujillo, Anna C Jones, Jeffrey K Griffith, Marco Bisoffi

引用次数: 54